Diffusion Pharmaceuticals Inc (DFFN.OQ)
DFFN.OQ on NASDAQ Stock Exchange Capital Market
0.55USD
20 Apr 2018
0.55USD
20 Apr 2018
Change (% chg)
$-0.02 (-3.16%)
$-0.02 (-3.16%)
Prev Close
$0.57
$0.57
Open
$0.58
$0.58
Day's High
$0.58
$0.58
Day's Low
$0.55
$0.55
Volume
15,704
15,704
Avg. Vol
152,693
152,693
52-wk High
$3.93
$3.93
52-wk Low
$0.50
$0.50
About
Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC)... (more)
Overall
| Beta: | -0.90 |
| Market Cap(Mil.): | $28.29 |
| Shares Outstanding(Mil.): | 50.53 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| DFFN.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 188.22 | 33.60 |
| EPS (TTM): | -0.32 | -- | -- |
| ROI: | -13.50 | -0.74 | 13.19 |
| ROE: | -24.44 | -2.80 | 15.00 |
BRIEF-Diffusion Pharmaceuticals Files Prospectus Related To Offering Of Common Stock
* DIFFUSION PHARMACEUTICALS INC FILES PROSPECTUS RELATED TO OFFERING UP TO 12.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2nGHE9Q) Further company coverage:
BRIEF-Diffusion Pharmaceuticals Announces $12 Mln Underwritten Public Offering
* DIFFUSION PHARMACEUTICALS ANNOUNCES $12 MILLION UNDERWRITTEN PUBLIC OFFERING
BRIEF-Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial With TSC In Glioblastoma Multiforme
* DIFFUSION PHARMACEUTICALS BEGINS PHASE 3 CLINICAL TRIAL WITH TSC IN GLIOBLASTOMA MULTIFORME
BRIEF-Diffusion Pharma Files For Stock Offering For Up To About $15 Mln
* DIFFUSION PHARMACEUTICALS FILES FOR STOCK OFFERING FOR UP TO ABOUT $15 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2BbtOBi) Further company coverage:
Estimates